Beclospin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Beclospin

Quick Facts

Property Description
Active ingredient Beclometasone dipropionate
Form Inhalation Aerosol or Nebuliser Suspension
Pharmacological class Synthetic Glucocorticoid (Corticosteroid)
Common purpose Prophylactic (preventive) therapy
Origin Synthetic

What Type of Medicine is Beclospin?

Beclospin is a synthetic medicinal preparation primarily used for its localized anti-inflammatory action within the respiratory system. It belongs to the potent pharmacological class of corticosteroids, specifically known as a Glucocorticoid agent. The medicine contains the active ingredient Beclometasone dipropionate, the International Nonproprietary Name (INN) for the compound, which acts as a prodrug. This means the substance is chemically inactive until converted into the therapeutically active form, Beclometasone 17-monopropionate, once it reaches the targeted tissue.


Composition and Form of the Beclometasone Preparation

The active substance, Beclometasone dipropionate, is formulated primarily for Inhalation and is commonly presented as a Nebuliser Suspension or a Pressurised Inhalation Aerosol (Metered Dose Inhaler). This specialized form and route of administration are essential for delivering the medication directly to the inflamed tissues in the airways. Unlike some older aerosol formulations, Beclospin preparations often utilize a non-CFC propellant, such as hydrofluoroalkane (HFA), which represents a distinct compositional feature. Beclospin is generally available as a single product (monotherapy), meaning it contains only the glucocorticoid agent, housed within a vehicle system to facilitate effective drug delivery.


General Purpose and Anti-inflammatory Action

The general purpose of Beclospin is to provide long-term, prophylactic therapy by controlling chronic inflammation within the airways. This medicine does not offer immediate relief but rather works slowly to suppress the immune cells that cause persistent swelling, irritation, and over-sensitivity in the respiratory passages. By acting as a Glucocorticoid receptor agonist, its mechanism helps to stabilize the patient's condition over time. Inhaled Beclometasone is used for maintenance therapy due to its topical potency and rapid metabolism, which contributes to its clinical profile in accordance with established medical guidelines.

What side effects are possible with Beclospin?

Possible Side Effects and Safety Information

As a synthetic Glucocorticoid administered by inhalation, Beclospin's safety profile is documented in official regulatory sources, detailing both local and systemic effects. Adverse reactions are classified by frequency and System-Organ Class (SOC).

Documented Adverse Reactions and Frequency

The most frequently reported adverse reaction is headache, which is classified as Very Common in certain regulatory documents. Common side effects typically involve the respiratory tract and gastrointestinal system, including oral candidiasis (thrush of the mouth and throat), hoarseness, cough, and various hypersensitivity reactions (e.g., rash, itching).

Organ Systems and Serious Safety Patterns

Official labeling organizes less frequent but serious adverse effects by the affected physiological system:

  • Immune System and Respiratory: A significant safety consideration is paradoxical bronchospasm, a Very Rare reaction involving an immediate increase in wheezing following inhalation. Severe hypersensitivity reactions, such as angioedema, are also documented.
  • Endocrine and Metabolic: Systemic effects such as adrenal suppression or features of Cushing's syndrome are documented as Very Rare occurrences, primarily associated with prolonged, high-dose exposure. This long-term use may also be associated with a decrease in bone mineral density.
  • Ocular: Glaucoma and cataracts are listed as Very Rare adverse reactions associated with chronic use.

Population-Specific Safety Considerations

Prolonged use in children and adolescents requires regular monitoring as regulatory documents note the potential for growth retardation. Furthermore, caution is advised in patients with existing active or quiescent pulmonary tuberculosis or other untreated systemic infections due to the immunosuppressive properties of corticosteroids. Safety notes may also advise caution in patients with severe hepatic impairment due to limited data.

Overdose and Emergency Response

The official regulatory profile for Beclospin (Beclometasone dipropionate) overdose focuses primarily on the consequences of chronic systemic toxicity resulting from the inhalation of very high dosages over a prolonged period. Acute, short-term inhalation of large amounts is generally expected to have minimal effect, with Hypothalamic-Pituitary-Adrenal (HPA) axis function recovering within a day or two.

Documented Manifestations and Emergency Action

The documented systemic manifestations associated with chronic overexposure include clinical signs of Hypercorticism and Adrenal Suppression. The risk of severe Adrenal Insufficiency is the most significant concern, as this can be life-threatening during periods of physiological stress, such as severe illness, trauma, or surgery.

Immediate medical attention must be sought if any clinical changes consistent with hypercorticism or signs of adrenal gland suppression are observed. Patients in the United States are instructed to call the Poison Help Line (1-800-222-1222). Medical management involves providing symptomatic and supportive treatment and, for confirmed chronic overdosage effects, the medicine must be slowly discontinued or tapered under medical supervision while HPA function is monitored. The official labeling for pediatric patients notes that growth retardation is a documented risk associated with prolonged, high-dose therapy, requiring close monitoring.

Therapeutic Uses of Beclospin

What Beclospin Treats: Main Uses and Benefits

The medication is generally used to provide long-term supportive management by addressing chronic inflammation in the airways. This preventive approach is considered relevant for the foundation of treatment in conditions such as persistent asthma and for specific maintenance treatment of moderate to severe COPD.

It is applied in clinical settings that involve recurrent or episodic manifestations of respiratory symptoms, primarily for asthma and COPD.

Control and Benefit

This treatment plays a role in managing symptom clusters that create noticeable physiological strain, helping to ease the overall burden of symptoms like wheezing, chest tightness, and chronic coughing. The medication may assist with easing the impact of respiratory issues on routine activities.

“This medication is applied across domains where additional symptomatic support is needed to minimize the frequency of disruptive episodes.”

This medicine is primarily designed for supportive management of chronic symptoms. It supports functional stability and may assist with easing the overall symptom load during periods of heightened symptoms.


Quick Fact: Symptomatic Support Focus

Domain Benefit
Asthma / COPD Assists with maintaining long-term stability.
Symptom Pattern May assist with reducing the frequency of wheezing and tightness.
Clinical Context Used as a daily controller medicine for prophylaxis.

Eligibility and Restrictions for Use

Official Eligibility Profile for Beclospin

Beclospin (beclometasone dipropionate) eligibility is strictly defined by government regulatory documents, focusing on populations for whom the medicine is safe and appropriate.

Eligibility Classification Populations/Conditions
Contraindicated Use Patients with known hypersensitivity or allergy to the active substance or any ingredient. The medicine is not indicated for the relief of acute bronchospasm or acute symptoms.
Age-Group Eligibility Approved for adults and children over 5 years for maintenance asthma treatment. For children up to 5 years, use is typically limited to recurrent wheezing and should not exceed three months unless an asthma diagnosis is confirmed.

Conditional Use and Restrictions:

Use requires special consideration and close medical monitoring in patients who are being transferred from systemic (oral) corticosteroids, due to the risk of adrenal insufficiency. Caution is also advised for individuals with active or latent infections, such as tuberculosis (TB), as well as those with a history of glaucoma, cataracts, or major risk factors for decreased bone mineral density. For women who are pregnant or breastfeeding, use is generally based on a careful assessment of the potential benefit versus the risk, with some regulatory documents recommending avoiding breastfeeding for four hours after taking high doses.

What should I know about interactions with other medicines?

Beclospin Interactions with other medicines and products

This section outlines interactions with other medicinal products and substances as documented in official government regulatory sources.

Interaction Type Interacting Medicines (Examples) Regulatory Constraint
Metabolic Inhibition Strong CYP3A Inhibitors: Ritonavir, Cobicistat Use with caution; monitor for systemic corticosteroid effects
Compositional Note Alcohol (Ethanol) Noted in some formulations; relevant for alcohol-sensitive medicines

Officially Documented Interaction Pattern

The primary interaction formally documented by regulatory authorities involves medicines that are strong inhibitors of the CYP3A enzyme system. This metabolic pathway plays a role in the clearance of Beclometasone's active metabolite (Beclometasone 17-monopropionate).

Concomitant use with strong CYP3A inhibitors is documented as carrying a risk for increased systemic exposure to the active metabolite. Although the inhaled route minimizes this risk compared to oral steroids, regulatory labels advise that caution and appropriate monitoring for signs of systemic corticosteroid effects are necessary if these potent inhibitors are co-administered.

Interaction-Related Restrictions

Regulatory documents do not classify any combination as a formal contraindication based on a specific drug-drug interaction mechanism. Furthermore, the official labels do not detail mandatory timing or separation rules for Beclospin doses relative to other medicines.

Some Beclospin inhalation formulations contain a small amount of ethanol (alcohol) as a compositional feature, a detail noted in regulatory documents that may be relevant to patients taking alcohol-sensitive medications.

Mechanism of Action

Targeting the Glucocorticoid Receptor and Gene Expression

The mechanism begins as the active drug binds to the intracellular Glucocorticoid Receptor (GR), initiating a complex genomic action. This interaction enables the drug to enter the cell nucleus and directly regulate the transcription of genes, primarily by transrepressing (downregulating) the activity of pro-inflammatory transcription factors like NF-kappaB. This molecular reprogramming is the fundamental step that shifts the cellular environment from an inflammatory state to one characterized by downregulated inflammatory gene expression.


Dampening Inflammatory Cascades and Mediator Synthesis

By modulating gene expression, Beclospin's mechanism leads to the widespread suppression of pro-inflammatory mediators, including potent signaling molecules like cytokines, chemokines, and the precursors to eicosanoids (prostaglandins and leukotrienes). This broad dampening effect reduces the chemical signals that normally attract and activate immune cells, such as eosinophils and mast cells, in the tissue.


Physiological Stabilization and Delayed Onset

The resulting decrease in inflammatory chemicals and immune cell activity leads to physiological consequences, including reduced local vascular permeability and decreased fluid extravasation. Because this mechanism relies on the slow process of gene transcription and protein synthesis, its effect is inherently delayed, explaining why the genomic-based mechanism exhibits a delayed onset over days, in contrast to mechanisms that produce rapid physiological responses.

Dosage and Administration Information

How to Use Beclospin (Beclometasone Dipropionate Inhalation)

Beclospin is an inhaled glucocorticoid preparation used for long-term, prophylactic maintenance therapy; it is not indicated for the immediate relief of acute breathing difficulties. The standard usage protocol centers on regular, specific administration via Oral Inhalation only.


Dosing and Frequency

Use is typically a twice-daily schedule (e.g., morning and evening), with the specific dose determined by prior therapy and disease severity. Adult patients generally start at 40 to 80 micrograms twice a day. The medicine's use is structured by a core principle of titration, where the dosage is continually adjusted downward to the lowest effective amount required to sustain control. The total daily dose for most HFA inhalation aerosols should not exceed 640 micrograms.


Administration Requirements

Feature Guidelines
Preparation The inhaler must be primed (actuated into the air) before first use or if unused for a specified period (e.g., 7 days).
Post-Dose Care Rinse the mouth and gargle with water without swallowing immediately after each dose to comply with administration instructions.
Pediatric Rule For children aged 5 to 11 years, the dose is typically 40 micrograms twice a day, with a maximum of 160 micrograms total daily dose.

Procedural Summary

Beclospin must be used regularly every day, even when symptoms are absent, as full benefit may require several weeks. The treatment should never be stopped abruptly; cessation or dose changes must be managed in accordance with professional guidance. If a dose is missed, it should be taken when remembered unless the next dose is due shortly, in which case the missed dose should be skipped.

Recent Clinical Evidence

Research evidence / Overview of studies for Beclospin


Evidence for Use in Persistent Asthma

This section will summarize the structure of Randomized Controlled Trials (RCTs) and Meta-Analyses that examined changes in lung function and symptom control.

The research exploring Beclospin for persistent asthma is largely built upon a substantial foundation of Randomized Controlled Trials (RCTs). Many of these trials were designed to compare the medicine against a placebo or another active comparator. These studies were used in research exploring how symptoms change over time and to monitor outcomes linked to inflammatory or irritative states in the airways. Research examined outcomes related to physical discomfort and episodic or acute changes. Study populations included adults, adolescents, and children, encompassing a wide range of patients from those with mild to those with severe, chronic asthma.

Studies monitored various outcomes over defined time intervals. Research describes measurements recorded during the study period, particularly in objective readings of pulmonary function (such as forced expiratory volume, or FEV1). Studies examined symptom intensity and monitored the use of quick-relief (rescue) inhalers. The evidence base also includes large-scale reviews that analyze data across many trials, which contributes to the available evidence landscape.


️ Evidence for Use in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

This section will outline the study landscape for COPD maintenance treatment, detailing the outcomes examined in controlled trials, particularly those tracking the frequency of acute exacerbations, and examining the level of evidence available for this indication.

The research conducted for moderate to severe COPD primarily involved Randomized Controlled Trials, in which the medicine was evaluated both alone and as a component of combination regimens. These studies were applied in research contexts involving fluctuating or unstable symptoms and conditions characterized by cycles of stability and flare-ups. The research focused on outcomes describing episodic or acute changes, specifically tracking the frequency of COPD flare-ups, known as exacerbation events.

Studies monitored outcomes related to episodic or acute changes, specifically tracking the frequency of exacerbation events. Some trials described patterns observed in the recorded exacerbation event rates. However, findings were mixed in studies that explored the outcomes related to the gradual decline of lung function (FEV1) over time. The evidence quality was observed to vary across studies for certain outcomes.

Frequently Asked Questions (FAQ)

Common questions about Beclospin (FAQ)


Q: How is Beclospin different from other medicines that treat the same condition?

A: Beclospin is a medicine belonging to the corticosteroid class (sometimes called a controller or preventer). Official information states its purpose is for long-term, prophylactic maintenance therapy, meaning it works slowly over time to control inflammation in the airways. It is not intended for the immediate relief of acute breathing difficulties.

Q: Do you get withdrawal symptoms when stopping Beclospin?

A: Official information advises that treatment with Beclospin should not be stopped abruptly. Patients who have used high doses for long periods may be susceptible to signs of adrenal insufficiency during times of stress, and this possibility is discussed in official regulatory documents.

Q: Is Beclospin the same as 'Beclo-something' I saw advertised?

A: Beclospin is the brand name, while its active substance is beclometasone dipropionate. This active substance may be available under different brand names or as a generic product, depending on the country. The official product labeling provides specific details regarding ingredients and formulation.

Q: Are there any specific foods or drinks to avoid while using Beclospin?

A: Regulatory documents do not list any specific foods or drinks that must be strictly avoided while using Beclospin. Official product information mentions that some formulations contain a small amount of ethanol (alcohol) as an inactive ingredient.

Q: Can people with high blood pressure use Beclospin?

A: Official labeling generally does not list high blood pressure as a contraindication for using Beclospin. However, official information indicates that caution is generally advised with conditions where the systemic effects of corticosteroids could be of concern.

Q: What does official research say about the long-term use of Beclospin?

A: Official regulatory documents note that long-term use, particularly at high doses, has been associated with effects such as decreased bone mineral density, adrenal suppression, and conditions like cataracts or glaucoma. Systemic effects are less likely with the inhaled form than with oral steroids.

Q: Why does the packaging list so many possible side effects?

A: Regulatory requirements mandate that official prescribing information must list all known adverse effects identified during clinical trials or through post-marketing surveillance. This is required regardless of how infrequently they occur.

Q: Does Beclospin cause weight gain?

A: Weight gain is not listed as a frequent side effect of Beclospin. However, prolonged use of very high doses may rarely lead to features associated with Cushing's syndrome, a condition known to be associated with body weight changes.

Q: Can Beclospin be used by older adults (seniors)?

A: Official product information suggests that for some formulations, no specific dose adjustment is required in elderly patients. However, the use of Beclospin is subject to individual evaluation, as older adults may be more susceptible to certain systemic effects.

Q: Does Beclospin affect mood or cause anxiety?

A: Official documents report that psychological or behavioral effects have been rarely noted with inhaled corticosteroids. These can include anxiety, depression, psychomotor hyperactivity, and sleep disorders.

Q: Do I need a special diet when taking Beclospin?

A: Regulatory documents do not specify a special diet that is required while using this medicine.

Q: Is there a generic version of Beclospin available?

A: The active ingredient in Beclospin is beclometasone dipropionate. Medicines containing this same active ingredient may be available from different companies as generic or alternative brand-name products. Official product information can clarify the specific ingredients and formulation of available products.

Q: What should I know about taking Beclospin with common pain relievers?

A: Regulatory documents primarily focus on interactions with strong CYP3A inhibitors. Official information notes that systemic corticosteroids can interact with certain pain relievers, such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), and emphasizes the importance of communicating all current medications to the prescribing professional.

Q: Are there any known interactions between Beclospin and supplements/herbal products?

A: Official regulatory labels focus on drug-drug interactions, such as those with CYP3A inhibitors. As a general safety measure, it is important to communicate all other medicines, supplements, or herbal products being taken to the prescribing professional.

Q: Does Beclospin impact blood sugar levels?

A: Corticosteroids, including Beclospin, may rarely cause systemic metabolic effects, particularly with prolonged use of high doses. These effects can include the risk of hyperglycemia (high blood sugar) in susceptible patients.

Q: Can I drive or operate machinery while using Beclospin?

A: Regulatory labels usually state that Beclospin is unlikely to affect the ability to drive or use machinery. However, if a patient experiences specific symptoms like blurred vision or dizziness, they should exercise caution.

Q: What is the expected duration of the effects of Beclospin after using it?

A: Beclospin is designed for long-term control and is typically administered on a twice-daily schedule (morning and evening) to maintain continuous preventive action. Regular daily use is required for the full effect.

Q: Does Beclospin contain lactose or gluten?

A: The specific inactive ingredients (excipients) of each unique Beclospin formulation will detail if substances like lactose or gluten are present. The official product information will list all components.

Q: Where can I find the official FDA/EMA information leaflet for Beclospin?

A: The official Prescribing Information (US) or Summary of Product Characteristics (EU) for a specific brand is publicly accessible. This information can be found via the online databases of government regulatory agencies like the FDA, EMA, or NIH’s DailyMed.

Q: Is it normal to feel a dry mouth or throat when using Beclospin?

A: Official regulatory labeling lists local side effects that often include hoarseness and throat irritation. This is why patients are generally advised to rinse their mouth and gargle with water immediately after each use.

Q: Can Beclospin affect sleep patterns?

A: Regulatory documents report that psychological effects, including sleep disorders, have been rarely reported with inhaled corticosteroids, particularly when high doses are prescribed for prolonged periods.

Q: Do studies suggest any potential long-term side effects not yet widely known?

A: Regulatory agencies continuously monitor the medicine's safety profile through post-marketing surveillance. Official labels are updated if new safety information or potential long-term risks are identified through ongoing studies or the patient reporting system.

Q: What is the shelf life of Beclospin once the package is opened?

A: The official product information provides specific handling and storage instructions, including any limitations on the product's 'in-use' shelf life after the first time it is actuated or opened.

Q: Is Beclospin available without a prescription in some countries?

A: Beclospin (beclometasone dipropionate inhalation) is classified as a prescription-only medicine in most major global markets. This classification is due to its potency as a corticosteroid intended for chronic, maintenance therapy.

Q: How is the safety of Beclospin monitored by regulatory bodies?

A: Regulatory bodies use pharmacovigilance systems to continuously monitor safety after the medicine is on the market. This involves collecting and reviewing reports of potential side effects from patients, consumers, and healthcare professionals.

Q: Are there specific tests I need before starting Beclospin?

A: The decision to start Beclospin is based on the patient's existing condition. While no specific universal screening tests are mandated before starting, regulatory labels advise regular monitoring of children's growth during long-term use.

Q: Does Beclospin interact with common cold or flu medications?

A: Official documents focus on interactions with specific medicines, such as strong CYP3A enzyme inhibitors. Patients are generally advised to check the ingredients of common cold or flu medicines, which may contain drugs that require caution.

Q: What is the difference between side effects and adverse reactions for Beclospin?

A: In regulatory documents, both terms refer to unwanted effects. Adverse reactions are specific unwanted effects where a clear causal link to the drug is known or strongly suspected, whereas the term side effects is often used more generally to describe any unwanted or unintended effect of a drug.

Q: What is the latest research or clinical trial phase for Beclospin?

A: Since Beclospin (Beclometasone dipropionate) is an established medicine, its initial clinical trial phase is complete. Ongoing research focuses on long-term safety, new delivery methods, or use in combination therapies, and findings are often registered on public databases like ClinicalTrials.gov.

Q: Do regulatory agencies classify Beclospin as a high-risk medication?

A: Beclospin is classified as a potent corticosteroid. Regulatory bodies manage its risk through strict labeling, required patient warnings, and pharmacovigilance, but it is not typically categorized as 'high-risk' when used as prescribed for chronic maintenance therapy.

Q: What should I do if I suspect an interaction with Beclospin?

A: Regulatory labels describe the importance of communicating all medicines, supplements, or herbal products being used to a healthcare professional, along with any unexpected or unusual symptoms experienced.

Q: How quickly does Beclospin usually start working?

A: Improvement in symptom control can occur within 24 hours for some patients, according to official information. However, the maximum therapeutic benefit that Beclospin provides typically requires 1 to 2 weeks or longer of regular daily use to achieve.

Q: Can I use alcohol while taking Beclospin?

A: Official labels advise caution for the co-administration of alcohol, and some formulations may contain ethanol as an inactive ingredient. The best practice is to adhere to the official advice.

How should Beclospin be stored and disposed of?

How to Store and Dispose of Beclospin?

The storage and disposal of Beclospin (Beclometasone dipropionate inhalation aerosol) are governed by specific regulatory requirements to ensure product stability and safety. This medication must be maintained at controlled room temperature—typically defined as below 25 C or 30 C—and requires mandatory protection from direct sunlight, freezing, and excessive heat to prevent damage to the pressurized canister. Always keep the inhaler out of the sight and reach of children in its original, tightly closed container.

Storage Restriction Requirement
Temperature Do not freeze or expose to heat above 50 C.
Container Integrity Do not puncture the canister or wash the device in water.
Discard Rule Dispose of the inhaler immediately when the labeled number of puffs is reached.

Disposal instructions strictly prohibit discarding the used or expired canister in household trash, wastewater, or fire. The product must be returned for disposal according to local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Beclospin found in:

A-Z Index: